Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use.

People with obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD) could be identified earlier and offered more appropriate treatment under draft NICE guidance published today.

Learn how NICE Advice’s system engagement service helps life sciences companies spot NHS adoption barriers before they become roadblocks.

NICE is unable to make a recommendation on brensocatib (Brinsupri) for treating non-cystic fibrosis bronchiectasis in people 12 years and over. This is because the company did not provide an evidence ...

Evidence-based recommendations on mirdametinib (Ezmekly) for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years ...